Status:
RECRUITING
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Colon Cancer
Neoadjuvant Therapy
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
There exists substantial evidence suggesting that patients diagnosed with MSI-H/dMMR colorectal cancer can derive benefits from immunotherapy in the management of advanced colorectal cancer. In cases ...
Eligibility Criteria
Inclusion
- Pathological confirmed rectal cancer
- Clinical stage T3-4 or T any N1
- With or without MRF positivity, with or without EMVI positivity
- R0 resection is estimated
- Age ranged from 18 to 70
Exclusion
- Clinical stage T1-2 N0
- Distance metastasis
- Multiple primary tumor
- Cachexy
Key Trial Info
Start Date :
July 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT06014372
Start Date
July 1 2023
End Date
July 1 2026
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China, 510060